Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioVie Inc.
  6. News
  7. Summary
    BIVI   US09074F2074

BIOVIE INC.

(BIVI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BioVie : B. Riley Raises BioVie's PT to $50 from $47 On Liver, Neurodegenerative, and Oncology Pipeline, Keeps Buy Rating

05/25/2021 | 09:40am EDT


© MT Newswires 2021
All news about BIOVIE INC.
10/14BIOVIE : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
10/14BIOVIE INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
10/13BIOVIE : Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance an..
AQ
09/22BIOVIE : to Present at Cantor Virtual Global Healthcare Conference
AQ
09/15BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit
GL
08/30BIOVIE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERAT..
AQ
08/30Biovie Inc. Reports Earnings Results for the Full Year Ended June 30, 2021
CI
08/30BioVie Inc. Contemplates Bankruptcy 
CI
08/11BIOVIE : Closes Common Stock Offering
MT
08/11BIOVIE : Announces Pricing of Public Offering of Common Stock (Form 8-K)
PU
More news
Analyst Recommendations on BIOVIE INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -181 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,09x
Yield 2022 -
Capitalization 139 M 139 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 6
Free-Float 19,9%
Chart BIOVIE INC.
Duration : Period :
BioVie Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 5,60 $
Average target price 50,00 $
Spread / Average Target 793%
EPS Revisions
Managers and Directors
Cuong Viet Do President, Chief Executive Officer & Director
Joanne Wendy Kim Chief Financial Officer & Secretary
Terren S. Peizer Chairman
Patrick Yeramian Chief Medical Officer
James D. Lang Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIOVIE INC.-67.67%139
GILEAD SCIENCES, INC.15.41%84 306
BIONTECH SE241.44%67 225
WUXI APPTEC CO., LTD.24.51%64 578
REGENERON PHARMACEUTICALS18.47%59 507
VERTEX PHARMACEUTICALS-22.35%47 610